Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity
Conclusion:Combining ACOX1-specific inhibitors with low-dose obeticholic acid effectively treats high-fat diet-induced hepatic steatosis and reduces serum LDL. This approach enhances the therapeutic effects of obeticholic acid and mitigates its lipotoxicity by inhibiting the IL-1β and α-SMA pathways.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Alcoholism | Diets | Drugs & Pharmacology | Fatty Liver Disease (FLD) | High Fat | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Study | Urology & Nephrology